Amgen Inc. (NASDAQ:AMGN) is Federated Hermes Inc.’s 5th Largest Position

Federated Hermes Inc. lessened its position in Amgen Inc. (NASDAQ:AMGN) by 30.4% during the fourth quarter, Holdings Channel.com reports. The fund owned 1,738,695 shares of the medical research company’s stock after selling 760,949 shares during the period. Amgen accounts for 1.2% of Federated Hermes Inc.’s holdings, making the stock its 5th largest holding. Federated Hermes Inc.’s holdings in Amgen were worth $500,779,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Southland Equity Partners LLC grew its holdings in Amgen by 2.3% in the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock worth $443,000 after acquiring an additional 34 shares during the last quarter. Acropolis Investment Management LLC grew its holdings in Amgen by 3.5% in the 4th quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock worth $288,000 after acquiring an additional 34 shares during the last quarter. Opal Wealth Advisors LLC grew its holdings in Amgen by 1.9% in the 4th quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock worth $538,000 after acquiring an additional 34 shares during the last quarter. Marino Stram & Associates LLC grew its holdings in Amgen by 0.7% in the 4th quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company’s stock worth $1,332,000 after acquiring an additional 34 shares during the last quarter. Finally, FORVIS Wealth Advisors LLC grew its holdings in Amgen by 1.4% in the 4th quarter. FORVIS Wealth Advisors LLC now owns 2,578 shares of the medical research company’s stock worth $743,000 after acquiring an additional 35 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on AMGN shares. TD Cowen cut their price target on shares of Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a report on Wednesday. Oppenheimer reissued an “outperform” rating and set a $350.00 price target on shares of Amgen in a research report on Thursday, February 1st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $329.00 target price on shares of Amgen in a report on Wednesday, April 3rd. StockNews.com cut shares of Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. Finally, UBS Group decreased their target price on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a report on Wednesday. Ten equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Amgen currently has an average rating of “Moderate Buy” and a consensus target price of $296.95.

Amgen Trading Up 0.1 %

Shares of NASDAQ AMGN traded up $0.28 during trading on Thursday, hitting $264.35. 437,135 shares of the company were exchanged, compared to its average volume of 2,829,316. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The company has a fifty day moving average price of $277.99 and a 200-day moving average price of $281.37. The firm has a market capitalization of $141.67 billion, a PE ratio of 21.14, a P/E/G ratio of 2.47 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.66 by $0.05. The firm had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. Amgen’s revenue was up 19.8% on a year-over-year basis. During the same period in the previous year, the firm earned $4.09 EPS. As a group, equities research analysts expect that Amgen Inc. will post 19.46 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 3.40%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.